Kyverna Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kyverna Therapeutics, Inc. (KYTX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-127.48-60.37-28.89-26.35
Depreciation & Amortization2.131.711.050.59
Stock Based Compensation8.362.220.937.25
Change in Working Capital7.863.42-10.33-4.49
Change in Accounts Payable0.744.080.680.01
Change in Other Working Capital7.12-0.66-3.980.83
Other Operating Activities2.541.721.410.83
Net Cash from Operating Activities-114.25-52.41-36.11-22.16
Investing Activities
Capital Expenditures-2.21-0.62-0.77-1.29
Purchases of Investments-158.70-8.16-13.330.00
Sales/Maturities of Investments331.30-8.1643.170.00
Other Investing Activities7.660.000.000.00
Net Cash from Investing Activities-160.90-8.79-14.10-1.29
Financing Activities
Debt Repayment-0.96-0.78-0.25-0.04
Common Stock Issued341.430.650.180.03
Other Financing Activities-3.36-1.650.000.00
Net Cash from Financing Activities337.1158.1211.8872.52
Summary
Net Change in Cash61.96-3.08-38.3349.08
Cash at Beginning of Period35.2138.2976.6227.54
Cash at End of Period97.1735.2138.2976.62
Free Cash Flow-116.46-53.03-36.88-23.44
Supplemental Disclosures
Interest Paid0.140.190.070.00